Publication date: Jul 17, 2026
To evaluate the incidence and epidemiological, clinical, and laboratory characteristics of Central Precocious Puberty (CPP) before, during, and after the COVID-19 pandemic in GoicE1s, Brazil. This retrospective, longitudinal, observational study with a quantitative approach was conducted in GoicE1s using administrative records of high-cost medication dispensing. All patients registered in the state dispensing center who initiated treatment between 2018 and 2023 were included. Data were analyzed using the Statistical Package for Social Sciences (IBM Corporation, Armonk, USA), version 26. 0. Statistical significance was set at 5% (p
| Concepts | Keywords |
|---|---|
| Central precocious puberty | |
| COVID-19 | |
| Gonadotropin-releasing hormone agonists | |
| Lockdown | |
| Puberty |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | precocious puberty |
| disease | MESH | COVID-19 pandemic |
| drug | DRUGBANK | MK-212 |
| disease | MESH | CPP |
| disease | MESH | included |
| disease | MESH | IBM |
| drug | DRUGBANK | Gonadorelin |
Original Article
(Visited 2 times, 1 visits today)